Search

Your search keyword '"Borlenghi E"' showing total 205 results
Start Over Author "Borlenghi E"
205 results on '"Borlenghi E"'

1. Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy

Author

Maurillo, L., Spagnoli, A., Candoni, A., Papayannidis, C., Borlenghi, E., Lazzarotto, D., Fianchi, L., Sciumè, M., Zannier, M.E., Buccisano, F., Del Principe, M.I., Mancini, V., Breccia, M., Fanin, R., Todisco, E., Lunghi, M., Palmieri, R., Fracchiolla, N., Musto, P., Rossi, G., and Venditti, A.

Published
2023
Full Text
View/download PDF

2. Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination.—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

Author

Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, Todisco, Elisabetta, Rossi, G, Borlenghi, E, Zappasodi, P, Lussana, F, Bernardi, M, Basilico, C, Molteni, A, Lotesoriere, I, Turrini, M, Frigeni, M, Fumagalli, M, Cozzi, P, Gigli, F, Cattaneo, C, Fracchiolla, N, Riva, M, Martini, G, Mancini, V, Cairoli, R, Todisco, E, Rossi, Giuseppe, Borlenghi, Erika, Zappasodi, Patrizia, Lussana, Federico, Bernardi, Massimo, Basilico, Claudia, Molteni, Alfredo, Lotesoriere, Ivana, Turrini, Mauro, Frigeni, Marco, Fumagalli, Monica, Cozzi, Paola, Gigli, Federica, Cattaneo, Chiara, Fracchiolla, Nicola Stefano, Riva, Marta, Martini, Gianluca, Mancini, Valentina, Cairoli, Roberto, and Todisco, Elisabetta

Abstract

A retrospective survey was conducted in hematologic centres of the Rete Ematologica Lombarda (REL) on 529 older AML patients seen between 2020–2022. Compared to 2008–2016, the use of intensive chemotherapy (ICT) decreased from 40% to 18.1% and of hypomethylating agents (HMAs) from 19.5% to 13%, whereas the combination of Venetoclax/HMA, initially not available, increased from 0% to 36.7%. Objective treatment-specific fitness criteria proposed by SIE/SIES/GITMO in 2013 allow an appropriate choice between ICT and HMAs by balancing their efficacy and toxicity. Venetoclax/HMA, registered for patients unfit to ICT, has a unique toxicity profile because of prolonged granulocytopenia and increased infectious risk. Aiming at defining specific fitness criteria for the safe use of Venetoclax/HMA, a preliminary investigation was conducted among expert REL hematologists, asking for modifications of SIE/SIES/GITMO criteria they used to select candidates for Venetoclax/HMA. While opinions among experts varied, a general consensus emerged on restricting SIE/SIES/GITMO criteria for ICT-unfit patients to an age limit of 80–85, cardiac function > 40%, and absence of recurrent lung infections, bronchiectasis, or exacerbating COPD. Also, the presence of an adequate caregiver was considered mandatory. Such expert opinions may be clinically useful and may be considered when treatment-specific fitness criteria are updated to include Venetoclax/HMA.

Published
2024

3. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, Martinelli G, Todisco, E, Papayannidis, C, Fracchiolla, N, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Gallo, S, Audisio, E, Griguolo, D, Cerchione, C, Selleri, C, Mattei, D, Bernardi, M, Fumagalli, M, Rizzuto, G, Facchini, L, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Roncoroni, E, Federico, V, Marconi, G, Volpi, R, Sciumè, M, Tarella, C, Rossi, G, Martinelli, G, Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S, Audisio E, Griguolo D, Cerchione C, Selleri C, Mattei D, Bernardi M, Fumagalli M, Rizzuto G, Facchini L, Basilico CM, Manfra I, Borlenghi E, Cairoli R, Salutari P, Gottardi M, Molteni A, Martini V, Lunghi M, Fianchi L, Cilloni D, Lanza F, Abruzzese E, Cascavilla N, Rivellini F, Ferrara F, Maurillo L, Nanni J, Romano A, Cardinali V, Gigli F, Roncoroni E, Federico V, Marconi G, Volpi R, Sciumè M, Tarella C, Rossi G, and Martinelli G

Abstract

Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax + HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60 days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax + HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax + HMA effectiveness and toxicities in real life.

Published
2023

4. Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Author

Venditti, A, Piciocchi, A, Soddu, S, Frigeni, M, Palmieri, R, Borlenghi, E, Fracchiolla, N, Martelli, M, Audisio, E, Gianfaldoni, G, Vetro, C, di Rienzo, N, Esposito, D, Di Veroli, A, Selleri, C, Gigli, F, Curti, A, Mulè, A, Califano, C, Bigliardi, S, Breccia, M, Fozza, C, Bocchia, M, Lico, A, Simonetti, F, Pierdomenico, E, Buccisano, F, Del Principe, M, Maurillo, L, Fazi, P, Vignetti, M, Ferrara, F, Cairoli, R, Rossi, G, Rambaldi, A, Venditti, Adriano, Piciocchi, Alfonso, Soddu, Stefano, Frigeni, Marco, Palmieri, Raffaele, Borlenghi, Erika, Fracchiolla, Nicola, Martelli, Maria Paola, Audisio, Ernesta, Gianfaldoni, Giacomo, Vetro, Calogero, di Rienzo, Nicola, Esposito, Daniela, Di Veroli, Ambra, Selleri, Carmine, Gigli, Federica, Curti, Antonio, Mulè, Antonino, Califano, Catello, Bigliardi, Sara, Breccia, Massimo, Fozza, Claudio, Bocchia, Monica, Lico, Albana, Simonetti, Federico, Pierdomenico, Elisabetta, Buccisano, Francesco, Del Principe, Maria Ilaria, Maurillo, Luca, Fazi, Paola, Vignetti, Marco, Ferrara, Felicetto, Cairoli, Roberto, Rossi, Giuseppe, Rambaldi, Alessandro, Venditti, A, Piciocchi, A, Soddu, S, Frigeni, M, Palmieri, R, Borlenghi, E, Fracchiolla, N, Martelli, M, Audisio, E, Gianfaldoni, G, Vetro, C, di Rienzo, N, Esposito, D, Di Veroli, A, Selleri, C, Gigli, F, Curti, A, Mulè, A, Califano, C, Bigliardi, S, Breccia, M, Fozza, C, Bocchia, M, Lico, A, Simonetti, F, Pierdomenico, E, Buccisano, F, Del Principe, M, Maurillo, L, Fazi, P, Vignetti, M, Ferrara, F, Cairoli, R, Rossi, G, Rambaldi, A, Venditti, Adriano, Piciocchi, Alfonso, Soddu, Stefano, Frigeni, Marco, Palmieri, Raffaele, Borlenghi, Erika, Fracchiolla, Nicola, Martelli, Maria Paola, Audisio, Ernesta, Gianfaldoni, Giacomo, Vetro, Calogero, di Rienzo, Nicola, Esposito, Daniela, Di Veroli, Ambra, Selleri, Carmine, Gigli, Federica, Curti, Antonio, Mulè, Antonino, Califano, Catello, Bigliardi, Sara, Breccia, Massimo, Fozza, Claudio, Bocchia, Monica, Lico, Albana, Simonetti, Federico, Pierdomenico, Elisabetta, Buccisano, Francesco, Del Principe, Maria Ilaria, Maurillo, Luca, Fazi, Paola, Vignetti, Marco, Ferrara, Felicetto, Cairoli, Roberto, Rossi, Giuseppe, and Rambaldi, Alessandro

Published
2023

5. Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Author

Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, Cairoli, Roberto, Gatti, A, Veronese, S, Grillo, G, Di Camillo, B, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, Magliano, G, Stefanucci, M, Brando, B, Beghini, A, Cairoli, R, Gatti, Arianna, Veronese, Silvio, Grillo, Giovanni, Di Camillo, Barbara, Fumagalli, Monica, Krampera, Mauro, Zappasodi, Patrizia, Borlenghi, Erika, Todisco, Elisabetta, Ubezio, Marta, Bernardi, Massimo, Molteni, Alfredo, Basilico, Claudia, Turrini, Mauro, Greco, Rosa, Mancini, Valentina, Riva, Marta, Magliano, Gabriele, Stefanucci, Marta Rachele, Brando, Bruno, Beghini, Alessandro, and Cairoli, Roberto

Published
2023

6. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

7. Validation of the 'fitness criteria' for the treatment of older patients with acute myeloid leukemia: A multicenter study on a series of 699 patients by the Network Rete Ematologica Lombarda (REL)

Author

Borlenghi, E, Pagani, C, Zappasodi, P, Bernardi, M, Basilico, C, Cairoli, R, Fracchiolla, N, Todisco, E, Turrini, M, Cattaneo, C, Da Via, M, Ciceri, F, Passamonti, F, Mancini, V, Sciume, M, Cerqui, E, Rossi, G, Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Via M, Ciceri F, Passamonti F, Mancini V, Sciume M, Cerqui E, Rossi G, Borlenghi, E, Pagani, C, Zappasodi, P, Bernardi, M, Basilico, C, Cairoli, R, Fracchiolla, N, Todisco, E, Turrini, M, Cattaneo, C, Da Via, M, Ciceri, F, Passamonti, F, Mancini, V, Sciume, M, Cerqui, E, Rossi, G, Borlenghi E, Pagani C, Zappasodi P, Bernardi M, Basilico C, Cairoli R, Fracchiolla N, Todisco E, Turrini M, Cattaneo C, Da Via M, Ciceri F, Passamonti F, Mancini V, Sciume M, Cerqui E, and Rossi G

Abstract

Objectives: Treatment of older patients with acute myeloid leukemia (AML) is still controversial. To facilitate treatment decisions, the “fitness criteria” proposed by Ferrara et al. (Leukemia, 2013), including age > 75 years, performance status and comorbidities, were verified retrospectively in 699 patients with AML (419 de-novo, 280 secondary AML), diagnosed at 8 Hematological Centers (REL). Methods: Patients were categorized in FIT to intensive chemotherapy (i-T) (292, 42.5%), UNFIT to i-T (289, 42.1%), or unfit even to non-intensive therapy (non i-T) (FRAIL) (105, 15.3%). Biological characteristics and treatment actually received by patients [i-T, 274 patients (39.2%); non i-T, 134 (19.2%), best-supportive care (BSC), 291 (41.6%)] were recorded. Results: “Fitness criteria” were easily applicable in 98.1% of patients. Overall concordance between “fitness criteria” and treatment actually received by patients was high (79.4%), 76% in FIT, 82.7% in UNFIT and 80% in FRAIL patients. Fitness independently predicted survival (median survival: 10.9, 4.2 and 1.8 months in FIT, UNFIT and FRAIL patients, respectively; p = 0.000), as confirmed also by multivariate analysis. In FRAIL patients, survival with any treatment was no better than with BSC, in UNFIT non i-T was as effective as i-T and better than BSC, and in FIT patients i-T was better than non i-T or BSC. In addition, a non-adverse risk AML, an ECOG PS <2, and receiving any treatment other than BSC had a favorable effect on survival (p < 0.001). Conclusion: These simple “fitness criteria” applied at the time of diagnosis could facilitate, together with AML biologic risk evaluation, the choice of the most appropriate treatment intensity in older AML patients.

Published
2021

8. When to suspect GATA2 deficiency in pediatric patients: from complete blood count to diagnosis

Author

Saettini, F, Coliva, T, Vendemini, F, Moratto, D, Savoldi, G, Borlenghi, E, Masetti, R, Niemeyer, C, Biondi, A, Balduzzi, A, Bonanomi, S, Saettini F., Coliva T., Vendemini F., Moratto D., Savoldi G., Borlenghi E., Masetti R., Niemeyer C. M., Biondi A., Balduzzi A., Bonanomi S., Saettini, F, Coliva, T, Vendemini, F, Moratto, D, Savoldi, G, Borlenghi, E, Masetti, R, Niemeyer, C, Biondi, A, Balduzzi, A, Bonanomi, S, Saettini F., Coliva T., Vendemini F., Moratto D., Savoldi G., Borlenghi E., Masetti R., Niemeyer C. M., Biondi A., Balduzzi A., and Bonanomi S.

Published
2021

9. S113: NATIONAL PEGASPARGASE-MODIFIED RISK-ORIENTED PROGRAM FOR PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA (PH− ALL/LL). GIMEMA LAL 1913 FINAL RESULTS.

Author

Bassan, R., primary, Chiaretti, S., additional, Della Starza, I., additional, Spinelli, O., additional, Santoro, A., additional, Elia, L., additional, De Propris, M. S., additional, Scattolin, A. M., additional, Paoloni, F., additional, Messina, M., additional, Audisio, E., additional, Marbello, L., additional, Borlenghi, E., additional, Zappasodi, P., additional, Vetro, C., additional, Martinelli, G., additional, Mattei, D., additional, Fracchiolla, N., additional, Bocchia, M., additional, De Fabritiis, P., additional, Bonifacio, M., additional, Candoni, A., additional, Cassibba, V., additional, Di Bartolomeo, P., additional, Latte, G., additional, Trappolini, S., additional, Guarini, A., additional, Vitale, A., additional, Fazi, P., additional, Vignetti, M., additional, Rambaldi, A., additional, and Foà, R., additional

Published
2022
Full Text
View/download PDF

10. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19

Author

Cattaneo, C, Daffini, R, Pagani, C, Salvetti, M, Mancini, V, Borlenghi, E, D'Adda, M, Oberti, M, Paini, A, De Ciuceis, C, Barbullushi, K, Cancelli, V, Belotti, A, Re, A, Motta, M, Peli, A, Bianchetti, N, Anastasia, A, Dalceggio, D, Roccaro, A, Tucci, A, Cairoli, R, Muiesan, M, Rossi, G, Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, Rossi G, Cattaneo, C, Daffini, R, Pagani, C, Salvetti, M, Mancini, V, Borlenghi, E, D'Adda, M, Oberti, M, Paini, A, De Ciuceis, C, Barbullushi, K, Cancelli, V, Belotti, A, Re, A, Motta, M, Peli, A, Bianchetti, N, Anastasia, A, Dalceggio, D, Roccaro, A, Tucci, A, Cairoli, R, Muiesan, M, Rossi, G, Cattaneo C, Daffini R, Pagani C, Salvetti M, Mancini V, Borlenghi E, D'Adda M, Oberti M, Paini A, De Ciuceis C, Barbullushi K, Cancelli V, Belotti A, Re A, Motta M, Peli A, Bianchetti N, Anastasia A, Dalceggio D, Roccaro AM, Tucci A, Cairoli R, Muiesan ML, and Rossi G

Abstract

Background: Patients with cancer are considered highly vulnerable to the recent coronavirus disease 2019 (COVID-19) pandemic. However, there are still few data on COVID-19 occurring in hematologic patients. Methods: One hundred two patients with COVID-19 symptoms and a nasopharyngeal swab positive for severe acute respiratory syndrome coronavirus 2 seen at 2 hematologic departments located in Lombardy, Italy, during March 2020 were studied. Risk factors for acquiring COVID-19 were analyzed by comparisons of patients with COVID-19 and the standard hematologic population managed at the same institutions in 2019. Thirty-day survival was compared with the survival of matched uninfected control patients with similar hematologic disorders and nonhematologic patients affected by COVID-19. Results: Male sex was significantly more prevalent in patients with COVID-19. The infection occurred across all different types of hematologic disease; however, the risk of acquiring a COVID-19 infection was lower for patients with chronic myeloproliferative neoplasms, including chronic myeloid leukemia, and higher for patients with immune-mediated anemia on immunosuppressive-related treatments. The 30-day mortality rate was 39.2%, which was higher than the rates for nonhematologic patients with COVID-19 (23.5%; P =.02) and uninfected hematologic controls (3%; P <.001). The severity of the respiratory syndrome at presentation and active hematologic treatment were independently associated with a worse prognosis. Neither diagnosis nor disease status affected the prognosis. The worst prognosis was demonstrated among patients on active hematologic treatment and those with more severe respiratory syndrome at COVID-19 presentation. Conclusions: During the COVID-19 pandemic, patients should be advised to seek medical attention at the earliest signs of dyspnea and/or respiratory infection. Physicians should perform a risk-benefit analysis to determine the impact of temporarily deferring nonlif

Published
2020

11. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial

Author

Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, and Lo-Coco F.

Published
2020

12. Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Author

Cairoli, R, Gatti, A, Grillo, G, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, De Marco, B, Stefanucci, M, Brando, B, Veronese, S, Beghini, A, Stefanucci, MR, Veronese, SM, Cairoli, R, Gatti, A, Grillo, G, Fumagalli, M, Krampera, M, Zappasodi, P, Borlenghi, E, Todisco, E, Ubezio, M, Bernardi, M, Molteni, A, Basilico, C, Turrini, M, Greco, R, Mancini, V, Riva, M, De Marco, B, Stefanucci, M, Brando, B, Veronese, S, Beghini, A, Stefanucci, MR, and Veronese, SM

Published
2022

13. High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study

Author

Cattaneo, C., Marchesi, F., Terrenato, I., Bonuomo, V., Fracchiolla, N. S., Delia, M., Criscuolo, Marianna, Candoni, A., Prezioso, L., Facchinelli, D., Pasciolla, C., Del Principe, M. I., Dargenio, M., Buquicchio, C., Mitra, M. E., Farina, F., Borlenghi, E., Nadali, G., Gagliardi, V. P., Fianchi, Luana, Sciume, M., Menna, P., Busca, A., Rossi, G., Pagano, Livio, Criscuolo M., Fianchi L., Pagano L. (ORCID:0000-0001-8287-928X), Cattaneo, C., Marchesi, F., Terrenato, I., Bonuomo, V., Fracchiolla, N. S., Delia, M., Criscuolo, Marianna, Candoni, A., Prezioso, L., Facchinelli, D., Pasciolla, C., Del Principe, M. I., Dargenio, M., Buquicchio, C., Mitra, M. E., Farina, F., Borlenghi, E., Nadali, G., Gagliardi, V. P., Fianchi, Luana, Sciume, M., Menna, P., Busca, A., Rossi, G., Pagano, Livio, Criscuolo M., Fianchi L., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

The potential drug-drug interactions of midostaurin may impact the choice of antifungal (AF) prophylaxis in FLT3-positive acute myeloid leukemia (AML) patients. To evaluate the incidence of invasive fungal diseases (IFD) during the treatment of FLT3-mutated AML patients and to correlate it to the different AF prophylaxis strategies, we planned a multicenter observational study involving 15 SEIFEM centers. One hundred fourteen patients treated with chemotherapy + midostaurin as induction/reinduction, consolidation or both were enrolled. During induction, the incidence of probable/proven and possible IFD was 10.5% and 9.7%, respectively; no statistically significant difference was observed according to the different AF strategy adopted. The median duration of neutropenia was similar in patients with or without IFD. Proven/probable and possible IFD incidence was 2.4% and 1.8%, respectively, during consolidation. Age was the only risk factor for IFD (OR, 95% CI, 1.10 [1.03–1.19]) and complete remission achievement after first induction the only one for survival (OR, 95% CI, 5.12 [1.93–13.60]). The rate of midostaurin discontinuation was similar across different AF strategies. The IFD attributable mortality during induction was 8.3%. In conclusion, the 20.2% overall incidence of IFD occurring in FLT3-mutated AML during induction with chemotherapy + midostaurin, regardless of AF strategy type, was noteworthy, and merits further study, particularly in elderly patients.

Published
2022

14. Rethinking the definition of 'less intensive' for venetoclax‐combining regimens in acute myeloid leukaemia patients.

Author

Borlenghi, E., Roccaro, A. M., and Cattaneo, C.

Subjects
*ACUTE myeloid leukemia, *DRUG monitoring, *MYCOSES, *PULMONARY aspergillosis, *ACUTE leukemia
Abstract

Invasive fungal infections (IFIs), mainly due to pulmonary aspergillosis, are considered a serious complication in acute leukaemia, with an unfavourable impact on patient. In this well‐conducted retrospective study, Reynolds et al. suggest that the use of posaconazole prophylaxis in association with venetoclax plus hypomethylating agents or chemotherapy leads to a reduction of IFI incidence. Therapeutic drug monitoring of posaconazole levels is suggested, even if no correlation with IFI risk has been demonstrated. Commentary on: Reynolds et al. Invasive fungal infection following venetoclax and posaconazole co‐administration. Br J Haematol 2023;203:593‐598. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Treatment of elderly patients with acute promyelocytic leukemia: A real life experience of the “rete ematologica lombarda”

Author

Mancini, V, Borlenghi, E, Leuzzi, L, Basilico, C, Bernardi, M, Zappasodi, P, Fumagalli, M, Todisco, E, Cattaneo, C, Lussana, F, Bertani, G, Ravelli, E, Fracchiolla, N, Turrini, M, Rossi, G, Cantoni, S, Cairoli, R, Mancini V., Borlenghi E., Leuzzi L., Basilico C., Bernardi M., Zappasodi P., Fumagalli M., Todisco E., Cattaneo C., Lussana F., Bertani G., Ravelli E., Fracchiolla N., Turrini M., Rossi G., Cantoni S., Cairoli R, Mancini, V, Borlenghi, E, Leuzzi, L, Basilico, C, Bernardi, M, Zappasodi, P, Fumagalli, M, Todisco, E, Cattaneo, C, Lussana, F, Bertani, G, Ravelli, E, Fracchiolla, N, Turrini, M, Rossi, G, Cantoni, S, Cairoli, R, Mancini V., Borlenghi E., Leuzzi L., Basilico C., Bernardi M., Zappasodi P., Fumagalli M., Todisco E., Cattaneo C., Lussana F., Bertani G., Ravelli E., Fracchiolla N., Turrini M., Rossi G., Cantoni S., and Cairoli R

Published
2019

16. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL

Author

Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, Lo-Coco, F, Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, and Lo-Coco F.

Published
2019

17. Acute leukemia and high-risk myelodysplastic syndromes in hiv positive patients: 25-years' experience of the rete ematologica lombarda (REL)

Author

Cattaneo, C, Bernardi, M, Mancini, V, Pagani, C, Fumagalli, M, Zappasodi, P, Borlenghi, E, Re, A, Ciceri, F, Sciumé, M, Cairoli, R, Rossi, G, Cattaneo C., Bernardi M., Mancini V., Pagani C., Fumagalli M., Zappasodi P., Borlenghi E., Re A., Ciceri F., Sciumé M., Cairoli R, Rossi G, Cattaneo, C, Bernardi, M, Mancini, V, Pagani, C, Fumagalli, M, Zappasodi, P, Borlenghi, E, Re, A, Ciceri, F, Sciumé, M, Cairoli, R, Rossi, G, Cattaneo C., Bernardi M., Mancini V., Pagani C., Fumagalli M., Zappasodi P., Borlenghi E., Re A., Ciceri F., Sciumé M., Cairoli R, and Rossi G

Published
2019

18. Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results

Author

Cairoli R, Krampera M, Zappasodi P, Todisco E, Borlenghi E, Molteni A, Fumagalli M, Ubezio M, Bernardi M, Greco Ravelli, E (Ravelli, Erika), Mancini V, Grillo G, Riva M, De Marco B, Cassaro A, Brando B, Gatti A, Veronese SM, Beghini A, Cairoli, R, Krampera, M, Zappasodi, P, Todisco, E, Borlenghi, E, Molteni, A, Fumagalli, M, Ubezio, M, Bernardi, M, Greco, R, E,, Erika), Mancini, V, Grillo, G, Riva, M, De Marco, B, Cassaro, A, Brando, B, Gatti, A, Veronese, S, and Beghini, A

Subjects
medicine.medical_specialty, business.industry, Immunology, Phases of clinical research, Consolidation Chemotherapy, Cell Biology, Hematology, Neutropenia, medicine.disease, Biochemistry, chemistry.chemical_compound, Regimen, chemistry, Maintenance therapy, Internal medicine, Cytarabine, Medicine, Midostaurin, business, Adverse effect, medicine.drug
Abstract

Genetic and Clinical Background: The clinical outcome of Core Binding Factor Leukemia (CBFL) seems influenced by the mutational status of KIT. In fact, several retrospective studies, in addition to our own, as well as a systematic review, indicate that KIT mutations have a negative prognostic impact in AML with t(8;21) or, to a lesser extent, with inv(16)/t(16;16). In addition, gene expression studies found KIT to be highly expressed in CBFL regardless of its mutational status. Furthermore, recent studies have identified novel recurrent somatic mutations co-occurring with KITmut. In-vitro studies revealed that Midostaurin (Mido) is effective in inhibiting both wild type (WT) and a range of KIT mutants. In addition, it is proven to be effective in KIT-positive malignancies such as Aggressive Systemic Mastocytosis (ASM), Mast Cell Leukemia (MCL), and SM with Associated Hematological Neoplasm (SM-AHN). With this background, we designed a Phase II trial to evaluate the safety and efficacy of Mido in association with Intensive Chemotherapy (IC), in CBFL regardless of KIT mutational status. Methods: The inclusion criteria were the following: age 18 to 60 years, diagnosis of de-novo CBFL, adequate organ function, signed informed consent. The exclusion criteria were: central nervous system involvement, uncontrolled infections, other active malignancies, a Qtc value greater than 470 ms (according to Bazett formula) at the electrocardiogram, significant uncontrolled or active cardiovascular diseases. Patients received standard induction therapy with an anthracycline containing regimen ("7+3"-like) + Mido, three cycles of post-remission consolidation chemotherapy with high-dose cytarabine + Mido, and 12 months of Mido as Maintenance. The Mido dosage was: 50 mg orally twice a day, on days 8-21, in association with IC, and 50 mg orally twice a day as single agent maintenance. In order to attain a reduction in 2 years Relapse Incidence (RI), from the historical value of 48% to 28% (Primary Objective of the Study), we plan to enrol 39 patients (power 82%, alpha error 4,6%). At diagnosis all patients were studied by a comprehensive NGS panel targeting 40 DNA genes and 29 RNA fusion driver genes. MRD status was assessed by qPCR and high-resolution multicolor flow cytometry at established check-points during consolidation and maintenance therapy. Results: 17 patients were enrolled between December 2018 to April 2020 (table1). Overall, the CR rate was 94.2%. At a median follow-up of 9 months (range 3-19 months), we recorded a RI of 12.5%, an OS of 93.7%, and a DFS of 81.2%. 16 patients continue on study and 14 patients are in 1st CR, MRD-negative by flow cytometry and qPCR. Six patients (35.2 %) experienced 12 Treatment Emergent Adverse Event (TEAE), 10 out of whom were infections, with grade 3-4 neutropenia (Table 2). We only recorded one death from SARS-Cov2 infection (Interstitial Pneumonia) in a patient in MRD-negative complete remission. There were no treatment-related deaths. Conclusion: In patients with CBFL, the regimen consisting of intensive chemotherapy and consolidation chemotherapy in association with Mido, followed by Mido maintenance, had an acceptable safety profile and excellent response rates with a significant proportion of patients in MRD-negative complete remission. Trial is continuing to accrue (EudraCT Number 2017-002094-18; ClinicalTrials ID: NCT 03686345). This work was supported by a grant from Fondazione Regionale per la Ricerca Biomedica (FRRB 2015). Disclosures Krampera: Janssen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Todisco:Jannsen, Abbvie, Jazz: Membership on an entity's Board of Directors or advisory committees. Veronese:Novartis: Other: Travel Expenses; Bayer: Honoraria; AstraZeneca: Other: Travel Expenses; Janssen Cilag: Honoraria. OffLabel Disclosure: Midostaurin for treatment of Core Binding Factor Leukemia. The drug has been used as KIT inhibitor.

Published
2020

19. OUTCOMES OF RELAPSED OR REFRACTORY AND NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA AFTER HYPOMETHYLATING AGENT AND VENETOCLAX. THE ITALIAN REAL-LIFE EXPERIENCE BEFORE PUBLIC HEALTH REIMBURSEMENT (AVALON STUDY)

Author

Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, Martinelli, G, Todisco, E, Papayannidis, C, Fracchiolla, N, Cerchione, C, Marconi, G, Petracci, E, Zingaretti, C, Vetro, C, Martelli, M, Zappasodi, P, Di Renzo, N, Cignetti, A, Lussana, F, Mattei, D, Ciceri, F, Facchini, L, Selleri, C, Fumagalli, M, Audisio, E, Griguolo, D, Basilico, C, Manfra, I, Borlenghi, E, Cairoli, R, Salutari, P, Gottardi, M, Molteni, A, Martini, V, Lunghi, M, Fianchi, L, Cilloni, D, Lanza, F, Abruzzese, E, Cascavilla, N, Rivellini, F, Ferrara, F, Maurillo, L, Nanni, J, Romano, A, Cardinali, V, Gigli, F, Vincenzo, F, Volpi, R, Sciume, M, Tarella, C, Rossi, G, and Martinelli, G

Published
2021

20. next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome -positive acute lymphoblastic leukemia

Author

Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, Sora, Federica (ORCID:0000-0002-9607-5298), Soverini, S, Martelli, M, Bavaro, L, De Benedittis, C, Papayannidis, C, Sartor, C, Sora', Federica, Albano, F, Galimberti, S, Abruzzese, E, Annunziata, M, Russo, S, Stulle, M, Imovilli, A, Bonifacio, M, Maino, E, Stagno, F, Basilico, Cm, Borlenghi, E, Fozza, C, Mignone, F, Minari, R, Stella, S, Baccarani, M, Cavo, M, Martinelli, G, and Sora, Federica (ORCID:0000-0002-9607-5298)

Abstract

BCR-ABL1 kinase domain mutation testing in tyrosine kinase inhibitor (TKI)-resistant Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) patients is routinely performed by Sanger sequencing (SS). Recently, next-generation sequencing (NGS)-based approaches have been developed that afford greater sensitivity and straightforward discrimination between compound and polyclonal mutations. We performed a study to compare the results of SS and NGS in a consecutive cohort of 171 Ph+ ALL patients. At diagnosis, 0/44 and 3/44 patients were positive for mutations by SS and NGS respectively. Out of 47 patients with haematologic resistance, 45 had mutations according to both methods, but in 25 patients NGS revealed additional mutations undetectable by SS. Out of 80 patients in complete haematologic response but with BCR-ABL1 ≥0·1%, 28 (35%) and 52 (65%) were positive by SS and NGS respectively. Moreover, in 12 patients positive by SS, NGS detected additional mutations. NGS resolved clonal complexity in 34 patients with multiple mutations at the same or different codons and identified 35 compound mutations. Our study demonstrates that, in Ph+ ALL on TKI therapy, NGS enables more accurate assessment of mutation status both in patients who fail therapy and in patients with minimal residual disease above 0·1%.

Published
2021

21. Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06

Author

Caprioli, C, Lussana, F, Salmoiraghi, S, Cavagna, R, Buklijas, K, Elidi, L, Zanghi', P, Michelato, A, Delaini, F, Oldani, E, Intermesoli, T, Grassi, A, Gianfaldoni, G, Mannelli, F, Ferrero, D, Audisio, E, Terruzzi, E, De Paoli, L, Cattaneo, C, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, A, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Falini, B, Pavoni, C, Bassan, R, Spinelli, O, Rambaldi, A, Caprioli, Chiara, Lussana, Federico, Salmoiraghi, Silvia, Cavagna, Roberta, Buklijas, Ksenija, Elidi, Lara, Zanghi', Pamela, Michelato, Anna, Delaini, Federica, Oldani, Elena, Intermesoli, Tamara, Grassi, Anna, Gianfaldoni, Giacomo, Mannelli, Francesco, Ferrero, Dario, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Cattaneo, Chiara, Borlenghi, Erika, Cavattoni, Irene, Tajana, Monica, Scattolin, Anna Maria, Mattei, Daniele, Corradini, Paolo, Campiotti, Leonardo, Ciceri, Fabio, Bernardi, Massimo, Todisco, Elisabetta, Cortelezzi, Agostino, Falini, Brunangelo, Pavoni, Chiara, Bassan, Renato, Spinelli, Orietta, Rambaldi, Alessandro, Caprioli, C, Lussana, F, Salmoiraghi, S, Cavagna, R, Buklijas, K, Elidi, L, Zanghi', P, Michelato, A, Delaini, F, Oldani, E, Intermesoli, T, Grassi, A, Gianfaldoni, G, Mannelli, F, Ferrero, D, Audisio, E, Terruzzi, E, De Paoli, L, Cattaneo, C, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, A, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Falini, B, Pavoni, C, Bassan, R, Spinelli, O, Rambaldi, A, Caprioli, Chiara, Lussana, Federico, Salmoiraghi, Silvia, Cavagna, Roberta, Buklijas, Ksenija, Elidi, Lara, Zanghi', Pamela, Michelato, Anna, Delaini, Federica, Oldani, Elena, Intermesoli, Tamara, Grassi, Anna, Gianfaldoni, Giacomo, Mannelli, Francesco, Ferrero, Dario, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Cattaneo, Chiara, Borlenghi, Erika, Cavattoni, Irene, Tajana, Monica, Scattolin, Anna Maria, Mattei, Daniele, Corradini, Paolo, Campiotti, Leonardo, Ciceri, Fabio, Bernardi, Massimo, Todisco, Elisabetta, Cortelezzi, Agostino, Falini, Brunangelo, Pavoni, Chiara, Bassan, Renato, Spinelli, Orietta, and Rambaldi, Alessandro

Abstract

Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of these features, uncertainties remain to identify the secondary nature of some cases otherwise defined as de novo AML. To test whether a chromatin-spliceosome (CS) mutational signature might better inform the definition of the de novo AML group, we analyzed a prospective cohort of 413 newly diagnosed AML patients enrolled into a randomized clinical trial (NILG AML 02/06) and provided with accurate cytogenetic and molecular characterization. Among clinically defined de novo AML, 17.6% carried CS mutations (CS-AML) and showed clinical characteristics closer to sAML (older age, lower white blood cell counts and higher rate of multilineage dysplasia). Outcomes in this group were adverse, more similar to those of sAML as compared to de novo AML (overall survival, 30% in CS-AML and 17% in sAML vs 61% in de novo AML, P<0.0001; disease free survival, 26% in CS-AML and 22% in sAML vs 54% of de novo AML, P<0.001) and independently confirmed by multivariable analysis. Allogeneic transplant in first complete remission improved survival in both sAML and CS-AML patients. In conclusion, these findings highlight the clinical significance of identifying CS-AML for improved prognostic prediction and potential therapeutic implications. (NILG AML 02/06: ClinicalTrials.gov Identifier: NCT00495287).

Published
2021

23. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL

Author

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts C, Hanel M, Rollig C, Schmitz N, Lin H, Frairia C, Fozza C, Maria D’Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Teresa Voso M, Ehninger G, Schlenk RF, Lo-Coco F., Cicconi, L, Platzbecker, U, Avvisati, G, Paoloni, F, Thiede, C, Vignetti, M, Fazi, P, Ferrara, F, Divona, M, Albano, F, Efficace, F, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Annibali, O, Wattad, M, Lubbert, M, Brandts, C, Hanel, M, Rollig, C, Schmitz, N, Lin, H, Frairia, C, Fozza, C, Maria D’Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Dohner, K, Ganser, A, Dohner, H, Amadori, S, Mandelli, F, Teresa Voso, M, Ehninger, G, Schlenk, R, and Lo-Coco, F

Subjects
Hematology
Published
2019

25. High throughput molecular characterization of normal karyotype acute myeloid leukemia in the context of the prospective trial 02/06 of the northern italy leukemia group (NILG)

Author

Salmoiraghi, S, Cavagna, R, Zanghì, P, Pavoni, C, Michelato, A, Buklijas, K, Elidi, L, Intermesoli, T, Lussana, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Audisio, E, Terruzzi, E, De Paoli, L, Borlenghi, E, Cavattoni, I, Mattei, D, Scattolin, A, Tajana, M, Ciceri, F, Todisco, E, Campiotti, L, Corradini, P, Fracchiolla, N, Bassan, R, Rambaldi, A, Spinelli, O, Salmoiraghi, Silvia, Cavagna, Roberta, Zanghì, Pamela, Pavoni, Chiara, Michelato, Anna, Buklijas, Ksenija, Elidi, Lara, Intermesoli, Tamara, Lussana, Federico, Oldani, Elena, Caprioli, Chiara, Stefanoni, Paola, Gianfaldoni, Giacomo, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Borlenghi, Erika, Cavattoni, Irene, Mattei, Daniele, Scattolin, Annamaria, Tajana, Monica, Ciceri, Fabio, Todisco, Elisabetta, Campiotti, Leonardo, Corradini, Paolo, Fracchiolla, Nicola, Bassan, Renato, Rambaldi, Alessandro, Spinelli, Orietta, Salmoiraghi, S, Cavagna, R, Zanghì, P, Pavoni, C, Michelato, A, Buklijas, K, Elidi, L, Intermesoli, T, Lussana, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Audisio, E, Terruzzi, E, De Paoli, L, Borlenghi, E, Cavattoni, I, Mattei, D, Scattolin, A, Tajana, M, Ciceri, F, Todisco, E, Campiotti, L, Corradini, P, Fracchiolla, N, Bassan, R, Rambaldi, A, Spinelli, O, Salmoiraghi, Silvia, Cavagna, Roberta, Zanghì, Pamela, Pavoni, Chiara, Michelato, Anna, Buklijas, Ksenija, Elidi, Lara, Intermesoli, Tamara, Lussana, Federico, Oldani, Elena, Caprioli, Chiara, Stefanoni, Paola, Gianfaldoni, Giacomo, Audisio, Ernesta, Terruzzi, Elisabetta, De Paoli, Lorella, Borlenghi, Erika, Cavattoni, Irene, Mattei, Daniele, Scattolin, Annamaria, Tajana, Monica, Ciceri, Fabio, Todisco, Elisabetta, Campiotti, Leonardo, Corradini, Paolo, Fracchiolla, Nicola, Bassan, Renato, Rambaldi, Alessandro, and Spinelli, Orietta

Abstract

By way of a Next-Generation Sequencing NGS high throughput approach, we defined the mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled into a prospective randomized clinical trial, designed to evaluate an intensified chemotherapy program for remission induction. NPM1, DNMT3A, and FLT3-ITD were the most frequently mutated genes while DNMT3A, FLT3, IDH1, PTPN11, and RAD21 mutations were more common in the NPM1 mutated patients (p < 0.05). IDH1 R132H mutation was strictly associated with NPM1 mutation and mutually exclusive with RUNX1 and ASXL1. In the whole cohort of NK-AML, no matter the induction chemotherapy used, by multivariate analysis, the achievement of complete remission was negatively affected by the SRSF2 mutation. Alterations of FLT3 (FLT3-ITD) and U2AF1 were associated with a worse overall and disease-free survival (p < 0.05). FLT3-ITD positive patients who proceeded to alloHSCT had a survival probability similar to FLT3-ITD negative patients and the transplant outcome was no different when comparing high and low-AR-FLT3-ITD subgroups in terms of both OS and DFS. In conclusion, a comprehensive molecular profile for NK-AML allows for the identification of genetic lesions associated to different clinical outcomes and the selection of the most appropriate and effective treatment strategies, including stem cell transplantation and targeted therapies.

Published
2020

26. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: Final results of the randomized Italian-German APL0406 trial

Author

Platzbecker, U, Avvisati, G, Cicconi, L, Thiede, C, Paoloni, F, Vignetti, M, Ferrara, F, Divona, M, Albano, F, Efficace, F, Fazi, P, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Wattad, M, Lübbert, M, Brandts, C, Hänel, M, Röllig, C, Schmitz, N, Link, H, Frairia, C, Pogliani, E, Fozza, C, D'Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Döhner, K, Ganser, A, Döhner, H, Amadori, S, Mandelli, F, Ehninger, G, Schlenk, R, Lo-Coco, F, Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F., Platzbecker, U, Avvisati, G, Cicconi, L, Thiede, C, Paoloni, F, Vignetti, M, Ferrara, F, Divona, M, Albano, F, Efficace, F, Fazi, P, Sborgia, M, Di Bona, E, Breccia, M, Borlenghi, E, Cairoli, R, Rambaldi, A, Melillo, L, La Nasa, G, Fiedler, W, Brossart, P, Hertenstein, B, Salih, H, Wattad, M, Lübbert, M, Brandts, C, Hänel, M, Röllig, C, Schmitz, N, Link, H, Frairia, C, Pogliani, E, Fozza, C, D'Arco, A, Di Renzo, N, Cortelezzi, A, Fabbiano, F, Döhner, K, Ganser, A, Döhner, H, Amadori, S, Mandelli, F, Ehninger, G, Schlenk, R, Lo-Coco, F, Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, and Lo-Coco F.

Abstract

Purpose: The initial results of the APL0406 trial showed that the combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the final analysis on the complete series of patients enrolled onto this trial. Patients and Methods: The APL0406 study was a prospective, randomized, multicenter, open-label, phase III noninferiority trial. Eligible patients were adults between 18 and 71 years of age with newly diagnosed, low- or intermediate-risk APL (WBC at diagnosis ≤ 10 × 109/L). Overall, 276 patients were randomly assigned to receive ATRA-ATO or ATRA-CHT between October 2007 and January 2013. Results: Of 263 patients evaluable for response to induction, 127 (100%) of 127 patients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arms, respectively (P = .12). After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and overall survival at 50 months for patients in the ATRA-ATO versus ATRA-CHT arms were 97.3% v 80%, 1.9% v 13.9%, and 99.2% v 92.6%, respectively (P < .001, P = .0013, and P = .0073, respectively). Postinduction events included two relapses and one death in CR in the ATRA-ATO arm and two instances of molecular resistance after third consolidation, 15 relapses, and five deaths in CR in the ATRA-CHT arm. Two patients in the ATRA-CHT arm developed a therapy-related myeloid neoplasm. Conclusion: These results show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that there is significantly greater and more sustained antileukemic efficacy of ATO-ATRA compared with ATRA-CHT in low- and intermediate-risk APL.

Published
2017

28. PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C, Spinelli, O, Salmoiraghi, S, Intermesoli, T, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Elidi, L, Delaini, F, Oldani, E, Gianfaldoni, G, Bosi, A, Marmont, F, Audisio, E, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Falini, B, Pavoni, C, Bassan, R, Rambaldi, A, and Lussana, F

Published
2019

29. Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?

Author

Malagola, M., Polverelli, N., Cancelli, V., Morello, E., Turra, A., Borlenghi, E., Cattina, F., Rambaldi, B., Bernardi, S., Zanaglio, C., Dereli Eke, Elif, Gandolfi, L., Farina, M., and Russo, D.

Subjects
Article Subject, hemic and lymphatic diseases
Abstract

We present a case of a patient with a three-month history of peripheral blood cytopenia without a confirmed diagnosis of myelodysplastic syndrome, who developed a favourable-risk acute myeloid leukemia (AML), according to the European Leukemia Net (ELN) criteria. The patient achieved a complete remission with incomplete platelet recovery (CRi) after induction. The patient achieved the morphological CR after the first consolidation and completed the first-line treatment with a syngeneic stem cell transplantation (SCT). A disease relapse occurred after one year of CR (blast cell count in the bone marrow 15%), and the patient was offered a haplo-SCT, which he refused due to personal reasons. In this paper, we discuss the interplay between clinical and biological risk factors in non-high-risk AML patients and speculate that some old clinical risk factors (e.g., age of the patient, achievement of CR after induction, and previous history of myelodysplastic syndrome) may still impact on the treatment decision algorithm of some of these patients.

Published
2019
Full Text
View/download PDF

32. MOLECULAR PROLIFE BY NEXT GENERATION SEQUENCING OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE: CLINICAL RESULTS FROM THE PROSPECTIVE TRIAL 02/06 OF THE NORTHERN ITALY LEUKEMIA GROUP (NILG)

Author

Spinelli, O, Salmoiraghi, S, Zanghi, P, Cavagna, R, Michelato, A, Buklijas, K, Zannino, L, Intermesoli, T, Lussana, F, Delaini, F, Oldani, E, Caprioli, C, Stefanoni, P, Gianfaldoni, G, Marmont, F, Ferrero, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Cavattoni, I, Tajana, M, Scattolin, Am, Mattei, D, Corradini, P, Campiotti, L, Ciceri, F, Bernardi, M, Todisco, E, Cortelezzi, A, Cortelazzo, S, Audisio, E, Bosi, A, Falini, B, Pavoni, C, Bassan, R, and Rambaldi, A

Published
2018

33. PF227 PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE

Author

Caprioli, C., primary, Spinelli, O., additional, Salmoiraghi, S., additional, Intermesoli, T., additional, Zanghì, P., additional, Cavagna, R., additional, Michelato, A., additional, Buklijas, K., additional, Elidi, L., additional, Delaini, F., additional, Oldani, E., additional, Gianfaldoni, G., additional, Bosi, A., additional, Marmont, F., additional, Audisio, E., additional, Ferrero, D., additional, Terruzzi, E., additional, De Paoli, L., additional, Rossi, G., additional, Borlenghi, E., additional, Cavattoni, I., additional, Tajana, M., additional, Scattolin, A.M., additional, Mattei, D., additional, Corradini, P., additional, Campiotti, L., additional, Ciceri, F., additional, Bernardi, M., additional, Todisco, E., additional, Cortelezzi, A., additional, Cortelazzo, S., additional, Falini, B., additional, Pavoni, C., additional, Bassan, R., additional, Rambaldi, A., additional, and Lussana, F., additional

Published
2019
Full Text
View/download PDF

34. PS1190 R-INTERFERON TREATMENT BEFORE TKI START IMPROVES TREATMENT FREE REMISSION RATE (TFR) PARTICULARLY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH THE LESS FAVORABLE E13A2 BCR-ABL1 TRANSCRIPT TYPE

Author

D’Adda, M., primary, Farina, M., additional, Passi, A., additional, Gramegna, D., additional, Daffini, R., additional, Ferrari, S., additional, Bottelli, C., additional, Borlenghi, E., additional, Cerqui, E., additional, Bertoli, D., additional, Archetti, S., additional, Marini, M., additional, and Rossi, G., additional

Published
2019
Full Text
View/download PDF

36. VALIDATING THE PATIENT'S 'FITNESS' CRITERIA PROPOSED TO GUIDE TREATMENT DECISION IN ELDERLY AML: A MULTICENTER STUDY ON A SERIES OF 699 PATIENTS BY THE NETWORK 'RETE EMATOLOGICA LOMBARDA'

Author

Borlenghi, E, Pagani, C, Basilico, C, Bernardi, M, Cairoli, R, Cortelezzi, A, Davia, M, Ferrario, A, Fracchiolla, N, Marbello, L, Messina, C, Santoro, A, Todisco, E, Turrini, M, Zappasodi, P, Cattaneo, C, Lamorgese, C, Rossi, G, Borlenghi, E, Pagani, C, Basilico, C, Bernardi, M, Cairoli, R, Cortelezzi, A, Davia, M, Ferrario, A, Fracchiolla, N, Marbello, L, Messina, C, Santoro, A, Todisco, E, Turrini, M, Zappasodi, P, Cattaneo, C, Lamorgese, C, and Rossi, G

Subjects
Hematology
Published
2016

37. EMERGING RESISTANT BACTERIA STRAINS IN ACUTE LEUKAEMIA PATIENTS: IS THERE STILL A ROLE FOR FLUOROQUINOLONE PROPHYLAXIS? RESULTS OF A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA (REL)

Author

Cattaneo, C, Zappasodi, P, Ferrari, S, Pavesi, F, Annaloro, C, Skert, C, Todisco, E, Ferrario, A, Sacca, V, Verga, L, Passi, A, Borlenghi, E, Da Via, M, Mancini, V, Mometto, G, Basilico, C, Cairoli, R, Nosari, A, Rossi, G, Cattaneo C, Zappasodi P, Ferrari S, Pavesi F, Annaloro C, Skert C, Todisco E, Ferrario A, Sacca V, Verga L, Passi A, Borlenghi E, Da Via M, Mancini V, Mometto G, Basilico C, Cairoli R, Nosari A, Rossi G., Cattaneo, C, Zappasodi, P, Ferrari, S, Pavesi, F, Annaloro, C, Skert, C, Todisco, E, Ferrario, A, Sacca, V, Verga, L, Passi, A, Borlenghi, E, Da Via, M, Mancini, V, Mometto, G, Basilico, C, Cairoli, R, Nosari, A, Rossi, G, Cattaneo C, Zappasodi P, Ferrari S, Pavesi F, Annaloro C, Skert C, Todisco E, Ferrario A, Sacca V, Verga L, Passi A, Borlenghi E, Da Via M, Mancini V, Mometto G, Basilico C, Cairoli R, Nosari A, and Rossi G.

Published
2015

38. NEXT GENERATION SEQUENCING (NGS) CONFIRMED THE ADVERSE CLINICAL IMPACT OF RUNX1 MUTATIONS IN A SUBSET OF ACUTE MYELOID LEUKEMIA NORMAL KARYOTYPE PATIENTS NEGATIVE FOR RISK DEFINING GENES MUTATIONS AND HOMOGENOUSLY TREATED WITHIN A CLINICAL TRIAL (NILG AML 02/06)

Author

Salmoiraghi, S, Zanghi, P, Pavoni, C, Montalvo, Mlg, Ubiali, G, Intermesoli, T, Oldani, E, Marmont, F, Cavattoni, I, Mattei, D, Terruzzi, E, De Paoli, L, Rossi, G, Borlenghi, E, Ciceri, F, Campiotti, L, Corradini, P, Cortelezzi, A, Ferrero, D, Audisio, E, Bosi, A, Bassan, R, Rambaldi, A, and Spinelli, O

Published
2017

39. CLINICAL SIGNIFICANCE OF END OF INDUCTION MINIMAL RESIDUAL DISEASE IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN COMPLETE REMISSION AFTER A SINGLE CHEMOTHERAPY COURSE

Author

Bassan, R, Masciulli, A, Intermesoli, T, Spinelli, O, Tosi, M, Pavoni, C, Audisio, E, Cattaneo, C, Fumagalli, M, Cassibba, V, Mattei, D, Romani, C, Cortelezzi, A, Ciceri, F, Scattolin, Am, Vitolo, U, Borlenghi, E, Gallamini, A, Depaoli, L, Campiotti, L, Bocchia, M, Di Bona, E, Oldani, E, and Rambaldi, A

Published
2017

40. EMERGING RESISTANT BACTERIA STRAINS IN ACUTE LEUKAEMIA PATIENTS: IS THERE STILL A ROLE FOR FLUOROQUINOLONE PROPHYLAXIS? RESULTS OF A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA (REL)

Author

Cattaneo, C., Zappasodi, P., Ferrari, S., Pavesi, F., Annaloro, C., Skert, C., Todisco, E., Ferrario, A., Sacca, V., Verga, L., Passi, A., Borlenghi, E., Matteo Claudio Da Vià, Mancini, V., Mometto, G., Basilico, C., Cairoli, R., Nosari, A., Rossi, G., Cattaneo, C, Zappasodi, P, Ferrari, S, Pavesi, F, Annaloro, C, Skert, C, Todisco, E, Ferrario, A, Sacca, V, Verga, L, Passi, A, Borlenghi, E, Da Via, M, Mancini, V, Mometto, G, Basilico, C, Cairoli, R, Nosari, A, and Rossi, G

Subjects
hematology
Published
2015

41. Antibiotic Prophylaxis Revisited: The Impact of Fluoroquinolones on Epidemiology and on the Emergence of Resistant Strains in Acute Leukemia Patients. Results of a Prospective Study By the Rete Ematologia Lombarda (REL)

Author

Cattaneo, C, Zappasodi, P, Ferrari, S, Pavesi, F, Annaloro, C, Skert, C, Verga, L, Todisco, E, Ferrario, A, Sacca, V, Passi, A, Borlenghi, E, Da Via, M, Mancini, V, Mometto, G, Basilico, C, Cairoli, R, Nosari, A, Rossi, G, Cattaneo C, Zappasodi P, Ferrari S, Pavesi F, Annaloro C, Skert C, Verga L, Todisco E, Ferrario A, Sacca V, Passi A, Borlenghi E, Da Via MC, Mancini V, Mometto G, Basilico C, Cairoli R, Nosari A, Rossi G., Cattaneo, C, Zappasodi, P, Ferrari, S, Pavesi, F, Annaloro, C, Skert, C, Verga, L, Todisco, E, Ferrario, A, Sacca, V, Passi, A, Borlenghi, E, Da Via, M, Mancini, V, Mometto, G, Basilico, C, Cairoli, R, Nosari, A, Rossi, G, Cattaneo C, Zappasodi P, Ferrari S, Pavesi F, Annaloro C, Skert C, Verga L, Todisco E, Ferrario A, Sacca V, Passi A, Borlenghi E, Da Via MC, Mancini V, Mometto G, Basilico C, Cairoli R, Nosari A, and Rossi G.

Published
2014

45. TWO-STEP RESPONSE-ORIENTED INDUCTION PREDICTS LONG-TERM OUTCOME OF ADULT PATIENTS WITH STANDARD- AND HIGH-RISK ACUTE MYELOID LEUKAEMIA (AML): A NORTHERN ITALY LEUKAEMIA GROUP (NILG) STUDY

Author

Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Oldani, E, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Fumagalli, M, Audisio, E, Fabris, P, Chisesi, T, Spinelli, O, Tosi, M, Giussani, U, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

46. IN ADULT ACUTE MYELOID LEUKAEMIA (AML) ALL RISK SUBSETS BENEFIT FROM A SEQUENTIAL HIGH-DOSE PROGRAMME AS EARLY RESCUE OF FIRST INDUCTION FAILURE: A REPORT FROM NORTHERN ITALY LEUKAEMIA GROUP (NILG)

Author

Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, F, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, Bassan, R, Intermesoli, T, Rossi, G, Pogliani, E, Marmont, F, Cavattoni, I, Cassibba, V, Scattolin, A, Musso, M, Mattei, D, Minotto, C, Ciceri, Fabio, Campiotti, L, Corradini, P, Borlenghi, E, Ruggeri, G, Terruzzi, E, Verga, L, Audisio, E, Fabris, P, Chisesi, T, Giussani, U, Spinelli, O, Zanghi, P, Oldani, E, Barbui, T, Rambaldi, A, and Bassan, R.

Published
2010

47. Improved Clinical Outcome of Adult Patients with Ph plus ALL After a Combined Imatinib-Chemotherapy Induction/Consolidation Program Followed by Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Prospective Study of the Northern Italy Leukemia Group

Author

Rambaldi A, Spinelli O, Oldani E, Grassi A, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, Lambertenghi Deliliers G, Mannelli F, Levis A, Mattei D, Borlenghi E, Terruzzi E, Borghero C, Romani C, Tosi M, Bussini A, Intermesoli T, Bassan R., CICERI , FABIO, Rambaldi, A, Spinelli, O, Oldani, E, Grassi, A, Rossi, G, Pogliani, Em, Di Bona, E, Angelucci, E, Cavattoni, I, Lambertenghi Deliliers, G, Mannelli, F, Levis, A, Ciceri, Fabio, Mattei, D, Borlenghi, E, Terruzzi, E, Borghero, C, Romani, C, Tosi, M, Bussini, A, Intermesoli, T, and Bassan, R.

Published
2010

50. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia

Author

Bassan, R., primary, Masciulli, A., additional, Intermesoli, T., additional, Audisio, E., additional, Rossi, G., additional, Pogliani, E. M., additional, Cassibba, V., additional, Mattei, D., additional, Romani, C., additional, Cortelezzi, A., additional, Corti, C., additional, Scattolin, A. M., additional, Spinelli, O., additional, Tosi, M., additional, Parolini, M., additional, Marmont, F., additional, Borlenghi, E., additional, Fumagalli, M., additional, Cortelazzo, S., additional, Gallamini, A., additional, Marfisi, R. M., additional, Oldani, E., additional, and Rambaldi, A., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results